August 05, 2013 / 19:48 IST
A fresh plea was filed with the Supreme Court against pharma major Ranbaxy Laboratories seeking cancellation of its manufacturing licence in the adulterated drug case.
It must be noted that on June 25, the apex court had dismissed a public interest litigation which had alleged that Ranbaxy manufactured and sold adulterated drugs. The petitioner had cited Ranbaxy’s case in US where in the drug company had admitted to selling substandard drugs and was later fined USD 500 million.
Also read: UCB files cases against Ranbaxy, Glenmark, and othersIn this fresh petition too, petitioner seeks to cancel the company’s manufacturing licence. The petition also seeks prosecution of the company's directors in the license case. In response to the plea the Supreme Court said that petitioner can file the documents to prove that the company sold adulterated drugs. The apex court will hear the plea on the August 12.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
